Cellectis Shares Dip Ahead of June Data Investors Wait For
Cellectis S.A. ADRs slipped Monday, with the U.S.-listed gene-editing biotech trading near session lows. Shares last quoted at $3.44, down 8 cents, or 2.3%. Cellectis opened at $3.55, hit a high of $3.69, and traded only 37,375 shares in light action. Cellectis shares dropped in a slumping biotech sector, with no new disclosure from the company. The SPDR S&P Biotech ETF finished down roughly 1.7%. The iShares Nasdaq Biotechnology ETF slid 1.4%. Cellectis’ most recent update on its press page was a May 20 announcement about its June 25 annual meeting.